Observational Safety Study of Meningococcal Conjugate Vaccine Against Serogroups A, C, W and Y (Menactra) Used in Routine Healthcare Practice for Persons Aged 2 to 55 Years in Russian Federation

Although incidence of invasive meningococcal disease (IMD) in the Russian Federation is low, children younger 15 years of age are significantly affected. Serogroups A, B, and C are frequently implicated. The quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) is approved in Russia for immunization of individuals 9 months to 55 years of age. Goals. We evaluated the safety of a single dose of MenACWY-D administered to individuals 2–55 years of age in routine clinical practice in the Russian Federation. Materials and Methods. Using diary cards filled by participants or their parents, this prospective multicenter observational study quantified the occurrence of solicited injection site and systemic reactions up to 7 days after vaccination as well as unsolicited non-serious adverse events (AEs), and serious adverse events (SAEs) for 28 days. Results. The systemicrate of solicited injection site and systemic reactions during the 7-day observation period was 52.0% (95% CI: 41.8; 62.2). Rates of solicited injection site reactions and systemic reactions of any severity were 49% (95% CI: 38.9; 59.2) and 20% (95% CI: 12.7; 29.2), respectively. The rate of unsolicited AEs was 9% (95% CI: 4.2; 16.4). Rates of solicited grade 3 injection site and systemic reactions ranged between 1–3% and 0–1%, respectively. There were no unsolicited adverse reactions (ARs), SAEs, or deaths. Conclusions. These findings  corroborate  those  of pre-licensure  and post-registration studies  and confirm  the safety  and good tolerability of MenACWY-D when used in routine clinical practice in individuals 2–55 years of age in the Russian Federation.

1. Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012; 30 (Suppl 2): B3-9. doi: 10.1016/j.vaccine.2011.12.062

2. World Health Organization (WHO). Meningococcal meningitis - Fact sheet. Geneva, Switzerland: World Health Organization (WHO); 2018 [updated February 19, 2018]. Available at: http://www.who.int/mediacentre/factsheets/fs141/en/ Accessed: 21 Aug 2018.

3. Harrison LH, Pelton SI, Wilder-Smith A, et al. The Global Meningococcal Initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011; 29 (18): 3363–71. doi: 10.1016/j.vaccine.2011.02.058

4. Xie O, Pollard AJ, Mueller JE, et al. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine. Vaccine. 2013;31(27):2852-61. doi: 10.1016/j.vaccine.2013.04.036

5. Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods in Molecular Biology. 2012;799:1-20. doi: 10.1007/978-1-61779-346-2_1

6. Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Population Health Metrics. 2013; 11 (1): 17. doi: 10.1186/1478-7954-11-17

7. Kaijalainen T, Kharit SM, Kvetnaya AS, et al. Invasive infections caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae among children in St Petersburg, Russia. Clinical Microbiololy and Infection. 2008; 14 (5): 507–10. doi: 10.1111/j.1469-0691.2008.01967.x

8. Titova I, Samodova O, Buzinov R, et al. Epidemiology of meningococcal infection in Arkhangelsk oblast. EpiNorth. 2010; 11: 10–5.

9. Maxina TA, Koroleva IS, Zakroeva IM, et al. Epidemiology of invasive meningococcal disease in Moscow, 2005–2010 (Poster E14). Meningitis and septicaemia in children and adults; London, UK: Meningitis Research Foundation; 2011.

10. Koroleva I, Beloshitski G, Zakroeva I, et al. Invasive meningococcal disease in the Russian Federation (Poster 014). EMGM conference (The European Meningococcal Disease Society); September 17–19, 2013; Bad Loipersdorf, Austria: The European Meningococcal Disease Society; 2013.

11. Polibin RV, Mindlina AY, Gerasimov AA, et al. Sravnitelny analiz smertnosti ot infektsionnykh zabolevanyi v Rossiyskoy Federatsii i nekotorykh stranakh Evropy. Epidemiology and Vaccine Prevention. 2017; 3 (94): 4–10 [in Russ]. doi: 10.31631/2073-3046-2017-16-3-4-10

12. Russian Reference Center on Monitoring for Bacterial Meningitis. Information and analytic review Meningococcal infection and purulent bacterial meningitis in the Russian Federation, 2016. Moscow, 2017.

13. Whittaker R, Dias JG, Ramliden M, et al. The epidemiology of invasive meningococcal disease in EU/EEA countries, 2004–2014. Vaccine. 2017; 35 (16): 2034–41. doi: 10.1016/j.vaccine.2017.03.007

14. Data from Russian Reference Center on Monitoring for Bacterial Meningitis of Rospotrebnadzor of Russian Federation.

15. Bilukha OO, Rosenstein N. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Reports, Recommendations and Reports. 2005; 54 (RR-7): 1–21

16. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Reports, Recommendations and Reports. 2013; 62 (RR-2): 1–28

17. Robertson CA, Greenberg DP, Hedrick J, et al. Safety and immunogenicity of a booster dose of meningococcal (groups A, C, W, and Y) polysaccharide diphtheria toxoid conjugate vaccine. Vaccine. 2016; 34 (44): 5273–8. doi: 10.1016/j.vaccine.2016.09.003

18. Ministry of Healthcare of the Russian Federation. Registration Certificate of Medicinal Drug. Menatra® vaccine for prevention of meningococcal infections. Certificate No. ЛП-002636 dated 22.09.2014. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=feb5d190-3f64-4061-ab27-a35af61dffbb. Accessed on: 24 Aug 2018.

19. Ministry of Healthcaere of Russian Federation. Menactra prescribing information. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=feb5d190-3f64-4061-ab27-a35af61dffbb. Accessed on: 24 Aug 2018.

20. Javadekar B, Ghosh A, Kompithra RZ, et al. Safety and immunogenicity of a two-dose schedule of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in Russian and Indian children aged 9 to 23 months. Indian Pediatr. (submitted for publication).

21. ClinicalTrials. gov. Observational safety study of Menactra® administered under standard health care practice in the Russian Federation (MTA92). Bethesda, MD: U.S. National Library of Medicine; 2016 [cited June 5, 2018]. Available at: https://clinicaltrials.gov/ct2/show/NCT02699840?term=MTA92&rank=1. Accessed 21 Aug 2018.

22. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika. 1934; 26 (4): 404–13. doi: 10.1093/biomet/26.4.404.

23. Sanofi Pasteur. Menactra®, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine Solution for Intramuscular Injection. Highlights of prescribing information. Swiftwater, PA: Sanofi Pasteur Inc; 2016 [revised April 2018]. Available at: https://www.vaccineshoppe.com/image.cfm?doc_id=12580&image_type=product_pdf. Accessed: 21 Aug 2018

24. Pina LM, Bassily E, Machmer A, et al. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. The Pediatric Infectious Disease Journal. 2012; 31 (11): 1173–83. doi: 10.1097/INF.0b013e318268dfe4.